Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference33 articles.
1. Aitken M, Blansett L, Mawrie R. Developments in cancer treatments, market dynamics, patient access and value. Parsippany: IMS Health; 2015.
2. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ. 2010;11(2):195–203.
3. Persson U. Value based pricing in Sweden: lessons for design? In: Office of Health Economics, editor. Seminar Briefing no 12; 2012.
4. Svensson M, Nilsson FO, Arnberg K. reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness. PharmacoEconomics. 2015;33(11):1229–36.
5. Olofsson S, Gerdtham UG, Hultkrantz L, Persson U. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay. Eur J Health Econ. 2017. https://doi.org/10.1007/s10198-017-0922-6 .
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献